Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-ABCA1 mRNA
- Development stage
- Preclinical
- Lead developer
- Fudan University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CAR-ABCA1 mRNA is an experimental mRNA-based therapeutic designed to reprogram macrophages for the treatment of atherosclerosis. Delivered via Ly6C-targeted lipid nanoparticles (Ly6C/LNPs), the mRNA encodes a dual-functional fusion construct consisting of a chimeric antigen receptor (CAR PS-FcRγ) and the ATP-binding cassette transporter A1 (ABCA1). The CAR component is engineered to enhance efferocytosis (the clearance of apoptotic cells) by binding to phosphatidylserine, while ABCA1 promotes cholesterol efflux, thereby preventing the formation of lipid-laden foam cells. By simultaneously addressing defective clearance and metabolic imbalances within atherosclerotic plaques, this therapy aims to stabilize lesions, reduce inflammation, and increase fibrous cap thickness.
- Other names
- Ly6C/LNP-CAR-ABCA1 mRNACAR-ABCA1 mRNA-LNPCAR-ABCA-1 mRNA-LNPCAR-ABCA 1 mRNA-LNP
02
Targets
FCER1G (Fc epsilon receptor I gamma subunit)ABCA1 (ATP-binding cassette transporter A1)
Beyond the preview
Go deeper on CAR-ABCA1 mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-ABCA1 mRNA.